Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

9.44
-0.2250-2.33%
Volume:382.06K
Turnover:3.56M
Market Cap:622.83M
PE:-2.51
High:9.68
Open:9.50
Low:9.09
Close:9.66
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:0.37
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:8.68
PE(LYR):-2.51

Loading ...

This biotech's stock is soaring after a 'polarizing' FDA official is stepping down

Dow Jones
·
Mar 09

REGENXBIO Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 09

Regenxbio price target lowered to $30 from $32 at H.C. Wainwright

TIPRANKS
·
Mar 09

RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty

TIPRANKS
·
Mar 07

REGENXBIO Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 07

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Kura Oncology (KURA)

TIPRANKS
·
Mar 06

Regenxbio price target lowered to $17 from $18 at Morgan Stanley

TIPRANKS
·
Mar 06

Regenxbio price target lowered to $42 from $45 at Stifel

TIPRANKS
·
Mar 06

BUZZ-Regenxbio falls as Q4 loss widens

Reuters
·
Mar 06

Regenxbio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 05

Regenxbio Q4 revenue rises but loss widens as costs increase

Reuters
·
Mar 05

Regenxbio Q4 R&D expenses rise 18.3% to USD 59.6 million

Reuters
·
Mar 05

BRIEF-Regenxbio Q4 License & Royalty Revenue USD 27.148 Million

Reuters
·
Mar 05

Regenxbio Q4 Operating Expenses USD 87.973 Million

THOMSON REUTERS
·
Mar 05

Regenxbio Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

THOMSON REUTERS
·
Mar 05

REGENXBIO to Present RGX-202 Duchenne Gene Therapy Data at MDA Clinical and Scientific Conference

Reuters
·
Mar 04

Rosen Law Firm Urges Regenxbio Investors to Meet April 14 Lead Plaintiff Deadline in Securities Class Action

Reuters
·
Mar 04

Regenxbio Inc expected to post a loss of 96 cents a share - Earnings Preview

Reuters
·
Mar 03

MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines -- Heard on the Street -- WSJ

Dow Jones
·
Mar 03

LEVI & KORSINSKY, LLP: RGNX DISCLOSURE TIMELINE REVEALS PATTERN OF ALLEGED INVESTOR HARM

TIPRANKS
·
Mar 03